Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event

Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event

October 23, 2015

- Phase 3 Studies in Myelodysplastic Syndromes ("MEDALIST") and Beta-thalassemia ("BELIEVE") Outlined -

- ACE-083 Preliminary Phase 1 Results Demonstrate 14% Increase in Muscle Volume -

- Acceleron Unveils IntelliTrap™ Platform to Design New Class of Highly Selective Inhibitors of TGF-beta Superfamily Ligands -

Moderna Launches Caperna LLC, Its Fourth Venture, to Develop Personalized Cancer Vaccines

Moderna Launches Caperna LLC, Its Fourth Venture, to Develop Personalized Cancer Vaccines

October 22, 2015

Caperna developing personalized cancer vaccines in combination with other cancer immunotherapies. Moderna finalizing the development of rapid cycle-time, small-batch GMP capabilities to support the development of personalized therapies.

Syros Pharmaceuticals Appoints Industry Leader Marsha H. Fanucci to Its Board of Directors

Syros Pharmaceuticals Appoints Industry Leader Marsha H. Fanucci to Its Board of Directors

October 19, 2015

Scientific Co-Founder James E. Bradner Steps Down from Board Following Appointment as President of NIBR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, the industry pioneer in gene control, today announced the appointment of Marsha H. Fanucci to the company’s Board of Directors. Ms. Fanucci brings 25 years of experience in biopharmaceutical financial management and strategic business operations.

Pronutria Biosciences Appoints Garry E. Menzel, Ph.D., as Chief Business and Strategy Officer

Pronutria Biosciences Appoints Garry E. Menzel, Ph.D., as Chief Business and Strategy Officer

October 19, 2015

Cambridge, Mass., October 19th, 2015 / BUSINESS WIRE / -- Pronutria Biosciences™ Inc., a biotechnology company pioneering a new class of therapeutics to mediate amino acid biology, announced today the appointment of Garry E. Menzel, Ph.D., as Chief Business and Strategy Officer.

Selecta Continues to Successfully Advance Pipeline of Novel Immunotherapeutic Candidates

Selecta Continues to Successfully Advance Pipeline of Novel Immunotherapeutic Candidates

October 16, 2015

Data related to Selecta’s targeted antigen-specific immune therapies presented at the American Society for Nanomedicine Annual Meeting

Novel therapies apply unique immune-modulating capabilities of Selecta’s Synthetic Vaccine Particle platform described in an article published in PNAS 

Agios Outlines Key Clinical Development & Research Strategies

Agios Outlines Key Clinical Development & Research Strategies

October 16, 2015

- Phase 3 Study of AG-221 in Relapsed/Refractory IDH2 Mutant Acute Myeloid Leukemia (IDHENTIFY) Initiated -

- Frontline Combination Development Strategy for AG-221 and AG-120 Announced -

- Second Pyruvate Kinase-R Activator AG-519 Entering Clinical Development -

- Company to Webcast Today's R&D Day -

Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis

Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis

October 15, 2015

-Eleven Granted Isunakinra as the International Nonproprietary Name for EBI-005-

Christopher A. Viehbacher Joins Pronutria Biosciences’ Board of Directors

Christopher A. Viehbacher Joins Pronutria Biosciences’ Board of Directors

October 15, 2015

Gurnet Point Capital Invests in Pronutria’s Series C Financing

BIND Therapeutics Expands Board of Directors with Appointment of Dr. Arthur Tzianabos

BIND Therapeutics Expands Board of Directors with Appointment of Dr. Arthur Tzianabos

October 14, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointment of Arthur Tzianabos, Ph.D., president and chief scientific officer of OvaScience, Inc., to the Company's board of directors.

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study

October 5, 2015

– Study Achieved its Primary Endpoint of Reduction in Viral Shedding; Treatment with VIS410 Resulted in a 92% Reduction of Virus vs. Placebo –

– Study Results Support Further Development of VIS410 in Hospitalized Patients with Influenza A –